Clinical Trial Update: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial updating napabucasin (BBI-608) with FOLFIRI in previously treated metastatic colorectal cancer has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• napabucasin (napabucasin)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-04-26